Mandatory low-testosterone screening for Army personnel could flag about one in four active-duty members, according to a JAMA study reported by Ars Technica. Researchers analyzed morning blood samples from 479 male soldiers and estimated that 26% would fall below the Pentagon's 300 ng/dL threshold. Using a lower CDC reference cutoff of 264 ng/dL, the estimated share drops to about 15%. The authors stress that published estimates of clinical hypogonadism are far lower, so many men with a single low reading would not actually have the condition.
Defense Secretary Pete Hegseth announced the mandatory screening in July, and the Pentagon released clinical guidance in September. The process begins with questions about symptoms and risk factors, but those criteria are broad: they include diminished physical performance, disturbed sleep, low motivation, obesity, type 2 diabetes, and low-trauma fractures. As a result, many service members could be referred for blood testing even without clear symptoms. The study measured all men in the sample, not just those who would pass the military's symptom and risk-factor questionnaire, so the actual share referred for testing may be lower.
Medical groups including the Endocrine Society and the American Urological Association have recommended against blanket screening. They warn that follow-up testing and testosterone replacement therapy carry potential harms, including infertility. For the military, the policy could mean a large wave of extra evaluations and long-term treatment costs, with uncertain clinical benefit.